8-KMaterial Agreements

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Jun 2, 2008)

Filed June 2, 2008For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant development in its pursuit of RNA interference (RNAi) therapeutics through a material definitive agreement with Takeda Pharmaceutical Company Limited, filed on June 2, 2008. This collaboration grants Takeda a worldwide, royalty-bearing license to Alnylam's intellectual property for the development and commercialization of RNAi therapeutics, initially focused on oncology and metabolic disease. The agreement represents a substantial validation of Alnylam's RNAi technology and provides significant financial backing. Takeda has committed to an upfront cash payment of $100.0 million, with additional payments contingent on achieving specific technology transfer, development, and commercialization milestones, as well as royalties on future product sales. This partnership is expected to accelerate the advancement of Alnylam's pipeline and broaden the potential reach of its innovative therapeutic approach.

Key Highlights

  • 1Alnylam entered into a material license and collaboration agreement with Takeda Pharmaceutical Company Limited on May 27, 2008.
  • 2The agreement grants Takeda a worldwide, royalty-bearing license to Alnylam's RNAi intellectual property.
  • 3The initial fields of focus for the collaboration are oncology and metabolic disease, with potential expansion to other therapeutic areas.
  • 4Takeda will make an upfront cash payment of $100.0 million to Alnylam.
  • 5Alnylam is eligible to receive milestone payments based on technology transfer, development, and commercialization achievements.
  • 6Royalty payments will be made by Takeda on sales of RNAi therapeutic products.
  • 7The collaboration includes joint research efforts on RNAi therapeutics and potential joint research on drug delivery technology.

Frequently Asked Questions

The agreement is a license and collaboration agreement to jointly pursue the development and commercialization of RNA interference (RNAi) therapeutics. Takeda gains a license to Alnylam's intellectual property in this field.

Alnylam will receive an upfront cash payment of $100.0 million from Takeda. Additionally, Alnylam is eligible for future milestone payments tied to development and commercialization success, as well as royalties on net sales of products developed under the agreement.

The license granted to Takeda is initially limited to the fields of oncology and metabolic disease. Takeda has the option to expand the license to include other therapeutic areas, subject to certain conditions.

The agreement can be terminated by either party for a material breach by the other. Takeda also has the right to terminate the agreement on a product-by-product or country-by-country basis after the first anniversary, provided that royalty payments for licensed products will continue.